Genfit has a number of on-going R&D programmes across multiple indications of global cardiometabolic risk. These programmes represent advanced research using a multimodal approach, which aims to treat and prevent a number of risk factors such as dyslipidemia, diabetes, obesity and atherosclerosis simultaneously.
What is Cardiometabolic Disease?
Cardiometabolic disease is a multifactoral epidemic, representing the leading cause of mortality worldwide and a major international health issue.
Genfit's Multimodal Approach
Genfit's multimodal approach is an innovative strategy to develop drugs with a single active ingredient to treat several risk factors simultaneously.
Genfit's Advanced Compound Status
Genfit has several compounds in clinical development: Learn more about the therapeutic positioning and development status of our most advanced drug development programmes.
